After the EMA in 2014 and the FDA in 2019, today the Therapeutic Goods Administration (TGA), Australia’s regulatory authority for therapeutic goods, has approved afamelanotide for EPP. TGA’s approval represents yet another milestone in recognizing afamelanotide as a valuable treatment for EPP and, at long last, Australian EPP sufferers are a step closer to accessing this therapy developed by Australia’s own biopharmaceutical company CLINUVEL. The IPPN now looks forward to an expeditious path to access, finally enabling Australian fellow patients to experience the life-changing benefits of afamelanotide.
